Successful comeback of the single-dose live oral cholera vaccine CVD 103-HgR

Travel Medicine and Infectious Disease

Volumn 14, Issue 4, 2016, Pages 373-377

  Herzog, Christian ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

Cholera; CVD 103 HgR; Oral live vaccine; Single dose

Indexed keywords

CHOLERA VACCINE; LIVE VACCINE;

ARTICLE; CHOLERA; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HIGH RISK POPULATION; HUMAN; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SINGLE DRUG DOSE; TRANSGENIC ORGANISM; TRAVEL; ADULT; FEMALE; IMMUNIZATION; IMMUNOLOGY; MALE; ORAL DRUG ADMINISTRATION; SWITZERLAND; VIBRIO CHOLERAE;

ADMINISTRATION, ORAL; ADULT; CHOLERA; CHOLERA VACCINES; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; MALE; SWITZERLAND; VACCINES, ATTENUATED; VIBRIO CHOLERAE;

EID: 84992598368     PISSN: 14778939     EISSN: 18730442     Source Type: Journal    
DOI: 10.1016/j.tmaid.2016.07.003     Document Type: Article

References (42)

1. [1] Harris, J.B., LaRocque, R.C., Qadri, F., Ryan, E.T., Calderwood, S.B., Cholera (seminar). Lancet 379 (2012), 2466–2476.
2. [2] Ali, M., Nelson, A.R., Lopez, A.L., Sack, D.A., Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis, 9, 2015, e0003832.
3. [3] World Health Organisation, Cholera: global surveillance summary 2009. Wkly Epid Rec 85 (2010), 293–308.
4. [4] World Health Organisation, Cholera, 2011. Wkly Epid Rec 87 (2012), 289–304.
5. [5] World Health Organisation, Cholera vaccines – WHO position paper. Wkly Epid Rec 85 (2010), 117–128.
6. [6] Thompson, K.M., Duintjer Tebbens, R.J., Chaignat, C.-L., Hill, A., Badizadegan, K., Costa, A.J., et al. Managing cholera as a preventable global threat. J Vaccines Vaccin, 4, 2013, 183.
7. [7] Deen, J., von Seidlein, L., Luquero, F.J., Troeger, C., Reyburn, R., Lopez, A.L., et al. The scenario approach for countries considering the addition of oral cholera vaccination in cholera preparedness and control plans. Lancet Infect Dis 16 (2016), 125–129.
8. [8] Fillion, K., Mileno, M.D., Cholera in travelers: shifting tides in epidemiology, management, and prevention. Curr Infect Dis Rep, 17, 2015, 455.
9. [9] Costa, M., Oberholzer-Riss, M., Hatz, C., Steffen, R., Puhan, M., Schlagenhauf, P., Pre-travel health advice guidelines for humanitarian workers: a systematic review. Travel Med Infect Dis 13 (2015), 449–465.
10. [10] Clemens, J.D., Shin, S., Sah, B.K., Sack, D.A., Cholera vaccines. Plotkin, S.A., Orenstein, W.A., Offit, P.A., (eds.) Vaccines, 6th ed., 2013, Saunders/Elsevier, Philadelphia, PA, USA, 141–152.
11. [11] Levine, M.M., Kaper, J.B., Live oral vaccines against cholera: an update. Vaccine 11 (1993), 207–212.
12. [12] Jackson, S.S., Chen, W.H., Evidence for CVD 103-HgR as an effective single-dose oral cholera vaccine. Future Microbiol 10 (2015), 1271–1281.
13. [13] World Health Organisation, Cholera, 2009. Wkly Epid Rec 85 (2010), 293–308.
14. [14] Azman, A.S., Luquero, F.J., Ciglenecki, I., Grais, R.F., Sack, D.A., Lessler, J., The impact of a one-dose versus two-dose oral cholera vaccine regimen in outbreak settings – a modeling study. PLoS Med, 12, 2015, e1001867.
15. [15] Viret, J.F., Dietrich, G., Favre, D., Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR. Vaccine 22 (2004), 2457–2469.
16. [16] Tacket, C.O., Cohen, M., Wasserman, S.S., Losonsky, G., Livio, S., Kotloff, K., et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination. Infect Immun 67 (1999), 6341–6345.
17. [17] Chen, W.H., Cohen, M.B., Kirkpatrick, B.D., Brady, R.C., Galloway, D., Gurwith, M., et al. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin Infect Dis 62 (2016), 1329–1335.
18. [18] Calain, P., Chaine, J.P., Johnson, E., Hawley, M.L., O'Leary, M.J., Oshitani, H., et al. Can oral cholera vaccination play a role in controlling a cholera outbreak?. Vaccine 22 (2004), 2444–2451.
19. [19] Richie, E., Punkabi, N.H., Sidharta, Y., Peetosutan, K., Sukandar, M., Wasserman, S.S., et al. Efficacy trial of single dose live oral cholera vaccine CVD 103-HgR in North Jakarta Indonesia, a cholera endemic area. Vaccine 18 (2000), 2399–2410.
20. [20] Chen, W.H., Greenberg, R.N., Pasetti, M.F., Livio, S., Lock, M., Gurwith, M., et al. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell bank. Clin Vaccine Immunol 21 (2014), 66–73.
21. [21] Kollaritsch, H., Fürer, E., Herzog, C., Wiedermann, G., Que, J.U., Cryz, S.J., Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines. Infect Immun 64 (1996), 1454–1457.
22. [22] Tsai, T.F., Kollaritsch, H., Que, J.U., Cropp, C.B., Kunz, C., Wiedermann, G., et al. Compatible concurrent administration of yellow fever 17D vaccine with oral, live, attenuated cholera CVD103-HgR and typhoid Ty21a vaccines. J Infect Dis 179 (1999), 522–524.
23. [23] Steffen, R., Acar, J., Walker, E., Zuckerman, J., Cholera: assessing the risk to travellers and identifying methods of protection. Travel Med Infect Dis 1 (2003), 80–88.
24. [24] World Health Organisation, Cholera 2005. Wkly Epid Rec 81 (2006), 297–307.
25. [25] Favre, D., Struck, M.M., Cryz, S.J., Viret, J.F., Further molecular characterization and stability of the live oral attenuated cholera vaccine strain CVD 103-HgR. Vaccine 14 (1996), 526–531.
26. [26] A phase 3 lot to lot consistency study of live oral cholera vaccine, PXVX200 in healthy adults. Available from: https://clinicaltrials.gov/ct2/show/NCT02094586?term=NCT02094586&rank=1 [Last accessed: 3.05.16].
27. [27] A study of live oral cholera vaccine, PXVX200 in healthy older adults. Available from: https://clinicaltrials.gov/ct2/show/NCT02100631?term=NCT02100631&rank=1 [Last accessed: 3.05.16].
28. [28] Vaxchora Prescribing Information (June 2016). Available from: http://www.vaxchora.com/Vaxchora_Prescribing_information.pdf [Last accessed: 7.07.16].
29. [29] PXVX0200 (CVD103-HgR) vs Shanchol in Mali. Available from: https://clinicaltrials.gov/ct2/show/NCT02145377?term=NCT02145377&rank=1 [Last accessed: 3.05.16].
30. [30] Waldman, R.J., Mintz, E.D., Papowitz, H.E., The cure for cholera –improving access to safe water. N Engl J Med 368 (2013), 592–594.
31. [31] Pape, J.W., Rouzier, V., Embracing oral cholera vaccine – the shifting response to cholera. N Engl J Med 370 (2014), 2067–2069.
32. [32] O'Leary, M., Mulholland, K., Oral cholera vaccines in endemic countries. Lancet 386 (2015), 1321–1322.
33. [33] World Health Organisation, Cholera 2014. Wkly Epid Rec 90 (2015), 517–544.
34. [34] Taylor, D.L., Kahawita, T.M., Caimcross, S., Ensink, J.H.J., The impact of water, sanitation and hygiene interventions to control cholera – a systematic review. PLoS One, 10, 2015, e0135676.
35. [35] Qadri, F., Ali, M., Chowdhury, F., Khan, A.I., Saha, A., Khan, I.A., et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh – a cluster randomised open-label trial. Lancet 386 (2015), 1362–1371.
36. [36] Sévère, K., Rouzier, V., Anglade, S.B., Bertil, C., Joseph, P., Deroncelay, A., et al. Effectiveness of oral cholera vaccine in Haiti: 37-Month follow-up. Am J Trop Med Hyg 94 (2016), 1136–1142.
37. [37] Phares, C.R., Date, K., Travers, P., Déglise, C., Wongjindanon, N., Ortega, L., et al. Mass vaccination with a two-dose oral cholera vaccine in a long-standing refugee camp, Thailand. Vaccine 34 (2016), 128–133.
38. [38] Ciglenecki, I., Sakoba, K., Luquero, F.J., Heile, M., Itama, C., Mengel, M., et al. Feasibility of mass vaccination campaign with oral cholera vaccines in response to an outbreak in Guinea. PLoS Med, 10, 2013, e1001512.
39. [39] Lucas, M.E., Deen, J.L., von Seidlein, L., Wang, X.Y., Ampuero, J., Puri, M., et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Engl J Med 352 (2005), 757–767.
40. [40] Luquero, F.J., Grout, L., Ciglenecki, I., Sakoba, K., Traore, B., Heile, M., et al. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med 370 (2014), 2111–2120.
41. [41] Qadri, F., Wierzba, T.F., Ali, M., Chowdhury, F., Khan, A.I., Saha, A., et al. Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh. N Engl J Med 374 (2016), 1723–1732.
42. [42] Harris, J.B., Resurrecting a live oral cholera vaccine. Clin Infect Dis 62 (2016), 1336–1337.